Zentalis Pharmaceuticals, Inc.
ZNTL
$1.51
$0.021.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.76% | -33.76% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.76% | -33.76% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -33.76% | -33.76% | -- | -- | -- |
| SG&A Expenses | 11.83% | 28.61% | 35.37% | 7.36% | 17.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.50% | -10.59% | 0.37% | 5.07% | 13.90% |
| Operating Income | 22.79% | 6.19% | 26.18% | 11.99% | 3.79% |
| Income Before Tax | 16.15% | -2.09% | 43.43% | 37.64% | 32.10% |
| Income Tax Expenses | -176.07% | 106.01% | 129.45% | 129.90% | 130.02% |
| Earnings from Continuing Operations | 16.40% | -2.37% | 43.26% | 37.37% | 31.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -100.00% | -75.44% | -52.38% | -67.71% |
| Net Income | 16.37% | -2.41% | 43.24% | 37.37% | 31.73% |
| EBIT | 22.79% | 6.19% | 26.18% | 11.99% | 3.79% |
| EBITDA | 22.81% | 6.17% | 26.28% | 12.02% | 3.77% |
| EPS Basic | 17.08% | 6.21% | 48.92% | 45.69% | 43.02% |
| Normalized Basic EPS | 0.95% | -12.78% | 39.57% | 43.07% | 40.13% |
| EPS Diluted | 17.14% | 6.27% | 48.91% | 45.69% | 43.02% |
| Normalized Diluted EPS | 0.97% | -12.76% | 39.55% | 43.06% | 40.12% |
| Average Basic Shares Outstanding | 0.94% | 4.38% | 8.72% | 14.09% | 20.58% |
| Average Diluted Shares Outstanding | 0.84% | 4.27% | 8.83% | 14.21% | 20.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |